<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03694925</url>
  </required_header>
  <id_info>
    <org_study_id>18-882</org_study_id>
    <nct_id>NCT03694925</nct_id>
  </id_info>
  <brief_title>Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty</brief_title>
  <official_title>Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether there are quantifiable differences in the&#xD;
      level of calprotectin in the synovial fluid that allow separation of different modes of joint&#xD;
      implant failure (e.g. infected, aseptic loosening). A subset of primary TKA patients (with&#xD;
      history of OA) will be included as a baseline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Calprotectin is a biomarker closely associated with leucocytes in general, and is present in&#xD;
      high volumes in neutrophil cells. Calprotectin is also produced by infiltrating monocytes and&#xD;
      macrophages, where calprotectin is released upon phagocytosis. In neutrophils, calprotectin&#xD;
      is stored intracellularly and are released upon activation of the cell. The determination of&#xD;
      number of neutrophils and proportion of neutrophils out of total number of inflammatory cells&#xD;
      is a diagnostic strategy commonly used in diagnosis of infection. Upon encounter with a&#xD;
      pathogen, neutrophils have several strategies to fight infections , and produce high-levels&#xD;
      of calprotectin. Activation of neutrophils, and release of calprotectin, can be for any&#xD;
      reason causing activation of the complement system and aseptic Inflammatory responses.&#xD;
      Moreover, Calprotectin is a danger associated molecular patterns (DAMP) signal influencing&#xD;
      the inflammatory responses. The level of activated neutrophils in PJI provide basis of the&#xD;
      presence of calprotectin in the synovial fluid of PJI patients, and thus, for calprotectin as&#xD;
      a potential biomarker for PJI. Calprotectin-levels in the synovial fluid do not merely&#xD;
      reflect the level of leucocytes and neutrophils present in the synovial fluid, but levels are&#xD;
      correlated to the WBC content. Calprotectin is likely to reflect the number of activated&#xD;
      cells and surpass the diagnostic accuracy of total WBC counts and neutrophil percentage for&#xD;
      PJI diagnosis.&#xD;
&#xD;
      A level of calprotectin of 50 mg/L in the synovial fluid has very good diagnostic accuracy&#xD;
      for PJI, supported by area under the curve values of more than 0.9. In a subgroup analysis&#xD;
      for patients with chronic PJI, a NPV of 97% was observed. The excellent NPV may assist in the&#xD;
      orthopaedic clinic to rule out the presence of infection and consider diagnostic alternatives&#xD;
      for aseptic loosening and pain revision of the joint patient. A rapid and accurate&#xD;
      distinction between these two causes is important as PJI and aseptic loosening are managed&#xD;
      differently with regards to surgical Intervention and followup.&#xD;
&#xD;
      Point of Care Test diagnostics by lateral flow devices provides reliable test results within&#xD;
      minutes of sample collection. Currently, Calprotectin can be detected by such lateral flow&#xD;
      devices (developed by Orthogenics, Tromsø, Norway). The speed and ease of use of this test&#xD;
      allows for diagnosis at patient's bed side. These tests can be applied in the physician's&#xD;
      office, operating room, an ambulance, the home, the field, or in the hospital. As the results&#xD;
      are timely they allow rapid diagnostic and identifies treatment alternatives for the patient.&#xD;
      This technology empowers clinicians to make decisions at the &quot;point-of-care&quot; and can have&#xD;
      significant impact on health care delivery and ability to address challenges of health&#xD;
      disparities. However, it is important to validate the diagnostic utility of calprotectin POC&#xD;
      in a diverse set of patients undergoing revision arthroplasty.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 29, 2018</start_date>
  <completion_date type="Actual">March 4, 2020</completion_date>
  <primary_completion_date type="Actual">January 7, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Calprotectin POC</measure>
    <time_frame>Day of surgery</time_frame>
    <description>lateral flow point of care test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Calprotectin ELISA</measure>
    <time_frame>Day of surgery</time_frame>
    <description>ELISA analysis</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">156</enrollment>
  <condition>Prosthetic Joint Infection</condition>
  <arm_group>
    <arm_group_label>Primary total knee arthroplasty</arm_group_label>
    <description>Primary TKA patients included in the study, to provide a baseline level for calprotectin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aseptic revision total knee arthroplasty</arm_group_label>
    <description>Aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Revision septic total knee arthroplasty</arm_group_label>
    <description>Septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Calprotectin test</intervention_name>
    <description>Calprotectin will be measured both by ELISA and point of care test.</description>
    <arm_group_label>Aseptic revision total knee arthroplasty</arm_group_label>
    <arm_group_label>Primary total knee arthroplasty</arm_group_label>
    <arm_group_label>Revision septic total knee arthroplasty</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Three groups:&#xD;
&#xD;
        Primary total knee arthroplasty Aseptic revision total knee arthroplasty Septic revision&#xD;
        total knee arthroplasty&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is ≥18 years of age&#xD;
&#xD;
          -  Patient with a diagnosis of OA (for primary TKA only)&#xD;
&#xD;
          -  Subject has had no recent injections or surgeries of the joint (within past 6 weeks)&#xD;
&#xD;
          -  Subject has or will have all of the medical tests required to allow MSIS&#xD;
             classification&#xD;
&#xD;
          -  Subject signs informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with a diagnostic synovial fluid specimen collection within the past 7 days&#xD;
&#xD;
          -  Results are not available for medical tests required to perform MSIS classification&#xD;
&#xD;
          -  Sample was obtained via lavage&#xD;
&#xD;
          -  Quantity not sufficient (at least 1 ml required)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Higuera, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic Florida</name>
      <address>
        <city>Weston</city>
        <state>Florida</state>
        <zip>33331</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>October 2, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <results_first_submitted>June 8, 2020</results_first_submitted>
  <results_first_submitted_qc>November 23, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 17, 2020</results_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Carlos Higuera-Rueda</investigator_full_name>
    <investigator_title>Chairman</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>The only group we will be sharing data with is the company (Lyfstone) which is funding the research.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 17, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/25/NCT03694925/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Primary Total Knee Arthroplasty</title>
          <description>Primary TKA patients included in the study, to provide a baseline level for calprotectin.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
        </group>
        <group group_id="P2">
          <title>Aseptic Revision Total Knee Arthroplasty</title>
          <description>Aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
        </group>
        <group group_id="P3">
          <title>Revision Septic Total Knee Arthroplasty</title>
          <description>Septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="53"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Inadequate laboratory testing</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Primary Total Knee Arthroplasty</title>
          <description>Primary TKA patients included in the study, to provide a baseline level for calprotectin.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
        </group>
        <group group_id="B2">
          <title>Aseptic Revision Total Knee Arthroplasty</title>
          <description>Aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
        </group>
        <group group_id="B3">
          <title>Revision Septic Total Knee Arthroplasty</title>
          <description>Septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="70"/>
            <count group_id="B3" value="53"/>
            <count group_id="B4" value="153"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67.2" spread="9.8"/>
                    <measurement group_id="B2" value="65.4" spread="10.6"/>
                    <measurement group_id="B3" value="68.8" spread="10.2"/>
                    <measurement group_id="B4" value="66.9" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="83"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.2" spread="5.9"/>
                    <measurement group_id="B2" value="32.0" spread="6.2"/>
                    <measurement group_id="B3" value="34.2" spread="9.7"/>
                    <measurement group_id="B4" value="33.2" spread="7.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Charlson Comorbidity Index</title>
          <description>The Charlson Comorbidity Index is a method of categorizing comorbidities of patients based on the International Classification of Diseases (ICD) diagnosis codes found in administrative data, such as hospital abstracts data. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted risk of mortality or resource use, and the sum of all the weights results in a single comorbidity score for a patient. Points are additionally added for age based on decade of life. A score of zero indicates that no comorbidities were found. Minimum is 0. Max is 27.</description>
          <units>units on a scale from 0 to 27</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.4" spread="2.0"/>
                    <measurement group_id="B2" value="3.4" spread="1.9"/>
                    <measurement group_id="B3" value="4.6" spread="2.5"/>
                    <measurement group_id="B4" value="3.8" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte Sedimentation Rate</title>
          <description>An erythrocyte sedimentation rate (ESR) is a type of blood test that measures how quickly erythrocytes (red blood cells) settle at the bottom of a test tube that contains a blood sample. Normally, red blood cells settle relatively slowly. A faster-than-normal rate may indicate inflammation in the body.</description>
          <population>ESR was not collected for primary TKA as it is not standard of care ESR was not ordered by the physician for 2 septic cases</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="51"/>
                    <count group_id="B4" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="14" spread="11"/>
                    <measurement group_id="B3" value="57" spread="35"/>
                    <measurement group_id="B4" value="33" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C Reactive Protein</title>
          <description>C-reactive protein (CRP) is a protein made by the liver. CRP levels in the blood increase when there is a condition causing inflammation somewhere in the body. A CRP test measures the amount of CRP in the blood to detect inflammation due to acute conditions or to monitor the severity of disease in chronic conditions.</description>
          <population>CRP was not collected for primary TKA as it is not standard of care CRP was not ordered by the physician for the 1 septic case</population>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0.6" spread="0.7"/>
                    <measurement group_id="B3" value="11.8" spread="14.6"/>
                    <measurement group_id="B4" value="5.4" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Synovial WBC Count</title>
          <population>Synovial WBC was not collected for primary TKA as it is not standard of care Synovial WBC was unable to be run due to insufficient quantity for the 1 septic case</population>
          <units>cells/ micro liter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="52"/>
                    <count group_id="B4" value="122"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="735" spread="856"/>
                    <measurement group_id="B3" value="57803" spread="66595"/>
                    <measurement group_id="B4" value="25059" spread="51598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Synovial PMN%</title>
          <population>Synovial PMN% was not collected for primary TKA as it is not standard of care Synovial PMN% was unable to be run due to insufficient quantity for 2 septic cases</population>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="51"/>
                    <count group_id="B4" value="121"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="21" spread="24"/>
                    <measurement group_id="B3" value="89" spread="13"/>
                    <measurement group_id="B4" value="50" spread="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smoker</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Type of Surgery</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Aseptic Revision</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAIR</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1st Stage of a 2 Stage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 Stage</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Primary</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Calprotectin POC Result</title>
          <description>Low Risk is defined 0-14 mg/L Medium Risk is defined as 14-50 mg/L High Risk is defined as &gt;50 mg/L&#xD;
The risk refers to risk of PJI</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Low Risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Calprotectin ELISA Result</title>
          <description>Low Risk is defined 0-14 mg/L Medium Risk is defined as 14-50 mg/L High Risk is defined as &gt;50 mg/L&#xD;
The risk refers to risk of PJI</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Low Risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate Risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Risk</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="153"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="52"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sinus Tract</title>
          <description>A tunneling wound or sinus tract is a narrow opening or passageway extending from a wound underneath the skin in any direction through soft tissue and results in dead space with potential for abscess formation.&#xD;
This was observed during surgery and collected from the operative note. This is not an outcome measure, rather it is used to assist in classifying a case as septic or aseptic using the Musculoskeletal Infection Society criteria for PJI. By definition all patients with a sinus tract are septic, however not all septic cases have a sinus tract.</description>
          <population>MSIS criteria was only applied to septic and aseptic cases.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cultures</title>
          <population>Cultures were not ordered on primary TKAs as they are not standard of care</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>2 or more positive cultures</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1 positive culture</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="47"/>
                    <measurement group_id="B4" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0 positive cultures</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="70"/>
                    <count group_id="B3" value="53"/>
                    <count group_id="B4" value="123"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Histopathology</title>
          <population>Histopathology was not ordered on primary TKAs as they are not standard of care.&#xD;
It was not ordered for a number septic and aseptic cases due to the individual preferences of the surgeon.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Positive</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="33"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="66"/>
                    <count group_id="B3" value="38"/>
                    <count group_id="B4" value="104"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Calprotectin POC</title>
        <description>lateral flow point of care test</description>
        <time_frame>Day of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Primary Total Knee Arthroplasty</title>
            <description>There will be n=30 primary TKA patients included in the study, to provide a baseline level for calprotectin.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
          </group>
          <group group_id="O2">
            <title>Aseptic Revision Total Knee Arthroplasty</title>
            <description>There will be n=70 aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
          </group>
          <group group_id="O3">
            <title>Revision Septic Total Knee Arthroplasty</title>
            <description>There will be n=50 septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
          </group>
        </group_list>
        <measure>
          <title>Calprotectin POC</title>
          <description>lateral flow point of care test</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive at &gt;50 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative at &gt;50 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive at &gt;14 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative at &gt;14 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Specificity</param_type>
            <param_value>.871</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Specificity was calculated using 2x2 tables using &gt;14 mg/L cut off. The numerator is the number of the true negatives and the denominator is the number of total negatives.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Specificity</param_type>
            <param_value>.957</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Specificity was calculated using 2x2 tables using &gt;50 mg/L cut off. The numerator is the number of the true negatives and the denominator is the number of total negatives.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Sensitivity</param_type>
            <param_value>.981</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Sensitivity was calculated using 2x2 tables using &gt;14 mg/L cut off. Sensitivity is the number of true positives over the number of total positives.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Sensitivity</param_type>
            <param_value>.981</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Sensitivity was calculated using 2x2 tables using &gt;50 mg/L cut off. Sensitivity is the number of true positives over the number of total positives.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Positive predictive value</param_type>
            <param_value>.852</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Positive predictive value was calculated using 2x2 tables using &gt;14 mg/L cut off. The numerator is the septic positives and the denominator are the total positives.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Positive predictive value</param_type>
            <param_value>.945</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Positive predictive value was calculated using 2x2 tables using &gt;50mg/L cut off. The numerator is the septic positives and the denominator are the total positives.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Negative predictive value</param_type>
            <param_value>.984</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Negative predictive value was calculated using 2x2 tables using &gt;14 mg/L cut off. The numerator is the aseptic negatives and the denominator is the number of total negatives.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Negative predictive value</param_type>
            <param_value>.985</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Negative predictive value was calculated using 2x2 tables using &gt;50 mg/L cut off. The numerator is the aseptic negatives and the denominator is the number of total negatives.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Calprotectin ELISA</title>
        <description>ELISA analysis</description>
        <time_frame>Day of surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Primary Total Knee Arthroplasty</title>
            <description>There will be n=30 primary TKA patients included in the study, to provide a baseline level for calprotectin.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
          </group>
          <group group_id="O2">
            <title>Aseptic Revision Total Knee Arthroplasty</title>
            <description>There will be n=70 aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
          </group>
          <group group_id="O3">
            <title>Revision Septic Total Knee Arthroplasty</title>
            <description>There will be n=50 septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
          </group>
        </group_list>
        <measure>
          <title>Calprotectin ELISA</title>
          <description>ELISA analysis</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="70"/>
                <count group_id="O3" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Positive at &gt;50 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative at &gt;50 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive at &gt;14 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative at &gt;14 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Specificity</param_type>
            <param_value>.829</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Specificity was calculated using 2x2 tables using &gt;14 mg/L cut off. The numerator is the number of the number of aseptic negatives and the denominator is the number of aseptics.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Specificity</param_type>
            <param_value>.957</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Specificity was calculated using 2x2 tables using &gt;50 mg/L cut off. The numerator is the number of the number of aseptic negatives and the denominator is the number of aseptics.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Sensitivity</param_type>
            <param_value>.981</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Sensitivity was calculated using 2x2 tables using &gt;14 mg/L cut off. Sensitivity is the number of septic positives over the number of septics.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Sensitivity</param_type>
            <param_value>.981</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Sensitivity was calculated using 2x2 tables using &gt;50 mg/L cut off. Sensitivity is the number of septic positives over the number of septics.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Positive predictive value</param_type>
            <param_value>.813</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Positive predictive value was calculated using 2x2 tables using &gt;14 mg/L cut off. The numerator is the septic positives and the denominator are the total positives.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Positive predictive value</param_type>
            <param_value>.945</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Positive predictive value was calculated using 2x2 tables using &gt;50mg/L cut off. The numerator is the septic positives and the denominator are the total positives.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Negative predictive value</param_type>
            <param_value>.983</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Negative predictive value was calculated using 2x2 tables using &gt;14 mg/L cut off. The numerator is the aseptic negatives and the denominator is the number of total negatives.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Negative predictive value</param_type>
            <param_value>.985</param_value>
            <ci_n_sides>2-Sided</ci_n_sides>
            <estimate_desc>Negative predictive value was calculated using 2x2 tables using &gt;50 mg/L cut off. The numerator is the aseptic negatives and the denominator is the number of total negatives.</estimate_desc>
            <other_analysis_desc>Negative predictive value was calculated using 2x2 tables using &gt;50 mg/L cut off. NPV=98.5%</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Area Under the Curve</title>
        <description>Area under the curve (AUC) was calculated using receiver operator characteristic (ROC) curve using the two cut offs (&gt;14 mg/L and &gt;50 mg/L) for both the ELISA and POC tests. Data were collected intraoperatively during the patient's arthroplasty surgery.&#xD;
AUC - ROC curve is a performance measurement for classification problem at various thresholds settings. ROC is a probability curve and AUC represents degree or measure of separability. It tells how much model is capable of distinguishing between classes. Higher the AUC, better the model is at predicting 0s as 0s (aseptics that are negative) and 1s as 1s (septics that are positive). 1.000 represents accurately predicting each aseptic as negatve and each septic as positive. While a 0.000 represents accurately predicting each aseptic as positive and each septic as negative.</description>
        <time_frame>From completion of first patient's ELISA and POC test to last patient's ELISA and POC test</time_frame>
        <population>Primary TKAs were no analyzed as AUC is a binary analysis representing the accuracy of predicting the correct diagnosis, ie (an aseptic is an negative, or a septic is positive). Arms/Groups are combined as the data represents the accuracy of all septics and aseptics combined at a given threshold for either the POC or ELISA test. This assessment was pre-specified to combine Arms.</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Total Knee Arthroplasty</title>
            <description>Primary TKA patients included in the study, to provide a baseline level for calprotectin.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
          </group>
          <group group_id="O2">
            <title>Combined Revision Total Knee Arthroplasty</title>
            <description>All revision TKA patients included in the study.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve</title>
          <description>Area under the curve (AUC) was calculated using receiver operator characteristic (ROC) curve using the two cut offs (&gt;14 mg/L and &gt;50 mg/L) for both the ELISA and POC tests. Data were collected intraoperatively during the patient's arthroplasty surgery.&#xD;
AUC - ROC curve is a performance measurement for classification problem at various thresholds settings. ROC is a probability curve and AUC represents degree or measure of separability. It tells how much model is capable of distinguishing between classes. Higher the AUC, better the model is at predicting 0s as 0s (aseptics that are negative) and 1s as 1s (septics that are positive). 1.000 represents accurately predicting each aseptic as negatve and each septic as positive. While a 0.000 represents accurately predicting each aseptic as positive and each septic as negative.</description>
          <population>Primary TKAs were no analyzed as AUC is a binary analysis representing the accuracy of predicting the correct diagnosis, ie (an aseptic is an negative, or a septic is positive). Arms/Groups are combined as the data represents the accuracy of all septics and aseptics combined at a given threshold for either the POC or ELISA test. This assessment was pre-specified to combine Arms.</population>
          <units>probability</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="123"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>POC Test &gt;50 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.969" lower_limit="0.934" upper_limit="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>POC Test &gt;14 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.926" lower_limit="0.875" upper_limit="0.978"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ELISA Test &gt;50 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.969" lower_limit="0.934" upper_limit="1.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ELISA Test &gt;14 mg/L</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.905" lower_limit="0.847" upper_limit="0.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected during the the collection of the synovial fluid sample on the day of surgery which was approximately 10 minutes from incision</time_frame>
      <desc>The clinicaltrials.gov definition was used</desc>
      <group_list>
        <group group_id="E1">
          <title>Primary Total Knee Arthroplasty</title>
          <description>There will be n=30 primary TKA patients included in the study, to provide a baseline level for calprotectin.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
        </group>
        <group group_id="E2">
          <title>Aseptic Revision Total Knee Arthroplasty</title>
          <description>There will be n=70 aseptic revision TKA patients included in the study. These are patients who are not considered infected according to Musculoskeletal Infection Society criteria for infection.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
        </group>
        <group group_id="E3">
          <title>Revision Septic Total Knee Arthroplasty</title>
          <description>There will be n=50 septic revision TKA patients included in the study. These are patients who are considered infected according to Musculoskeletal Infection Society criteria for infection.&#xD;
Calprotectin test: Calprotectin will be measured both by ELISA and point of care test.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="53"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alison Klika</name_or_title>
      <organization>Cleveland Clinic Arthroplasty Research Group</organization>
      <phone>4123017914</phone>
      <email>klikaa@ccf.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

